GlycoMimetics, Inc.

215 articles with GlycoMimetics, Inc.

• GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences

  11/10/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthc

• GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020

  11/6/2020

  Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continues on track, and the Company reiterates its prior guidance that completion of enrollment for the Company-sponsored Phase 3 trial is expected in the second half of 2021

• GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

  11/4/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company’s clinical and research portfolio have been accepted for oral presentations and two abstracts have been accepted for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually December 5-8, 2020.

• GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020

  10/30/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 3073766. Participants are encouraged to connect 15 minutes in advance

• New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

  10/26/2020

  Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and GMI-1687, accepted for poster and oral presentations ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the

• Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

  10/26/2020

  Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13 th Clinical Trials on Alzheimer's Disease (CTAD) Conference

• FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

  10/5/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger.

• GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference

  9/8/2020

  GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will present at the upcoming H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020.

• GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  9/4/2020

  GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that on August 14, 2020 the compensation committee of the Company’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 47,800 shares of its common stock to three new employees. The options were granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASD

• New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival

  8/31/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemia (AML) to overcome resistance to venetoclax and hypomethylating agent (HMA)-based therapy.

• GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020

  7/31/2020

  Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continued, and the company affirmed second half of 2021 as target for completion of enrollment A post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) produced new efficacy data showing statistically significa

• GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020

  7/24/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of

• GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  7/10/2020

  GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on July 6, 2020 of a non-qualified stock option award to purchase an aggregate of 12,200 shares of its common stock to a new employee. The options were granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ List

• New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting

  6/12/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occlusive crisis (VOC) shows that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placeb

• GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference

  5/29/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Thursday, June 4 from 1:00 – 1:25 p.m. EDT. To access the live webcast and subsequent archived recordings for the presentation, please

• GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020

  5/15/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24.

• GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders

  5/8/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meet

• GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020

  5/1/2020

  GlycoMimetics, Inc., Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million.

• Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications

  4/30/2020

  Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance

• GlycoMimetics to Report First Quarter Financial Results on May 1, 2020

  4/24/2020

  GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the “Investors” tab on th